ArticleCell & bioscience2026
ERO1L induces macrophage infiltration to potentiate Kras
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Pancreatitis is a significant risk factor for pancreatic cancer, with Kras mutations being the most common in this malignancy. Inflammation accelerates tumorigenesis driven by Kras mutations. However, the interactions between inflammation and Kras mutation in the context of pancreatic tumorigenesis remain unclear. In this study, we discovered that under pancreatitis conditions, the endoplasmic reticulum stress-related pathways are downregulated in Kras mutant mice compared to wild-type mice, while endoplasmic reticulum oxidoreductase 1 alpha (ERO1L) is abnormally upregulated. Kras mutation downregulates the ER-associated E3 ubiquitin ligase HRD1, resulting in reduced ubiquitination and degradation of HIF1α, which transcriptionally induces the expression of ERO1L. Inhibition of ERO1L activity or pancreas-specific knockout of the Ero1l gene can delay the progression of pancreatic carcinogenesis. Mechanistically, ERO1L enhances the protein expression of the chemokine CCL2 through its role in oxidative folding, thereby promoting the recruitment of macrophages. Thus, this study reveals that Kras mutation upregulates ERO1L to promote inflammation and pancreatic tumorigenesis, providing new insights and potential targets for the treatment of pancreatic cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.